文献速递心血管妇产影像MR

应用心脏磁共振首过灌注评估妇科恶性肿瘤化疗患者的心肌微血管功能

Myocardial microvascular function assessed by CMR first-pass perfusion in patients treated with chemotherapy for gynecologic malignancies.
PubMed 文献 · Eur Radiol · 2022-05-17

前瞻性纳入81例接受化疗的妇科恶性肿瘤患者和39名健康志愿者行心脏磁共振检查,其中32例患者完成中位间隔6个月的随访。患者心肌灌注指数低于正常对照,且灌注指数降低与化疗治疗独立相关,但与化疗周期数无显著相关。静息心脏磁共振首过灌注可用于评估和监测化疗期间心肌微循环改变。

要点

  • 化疗患者静息心肌灌注指数较健康对照降低,提示化疗相关心肌微血管功能障碍。
  • 心肌灌注指数降低与化疗治疗独立相关,但与化疗周期数无显著相关。
  • 静息心脏磁共振首过灌注可用于评估和监测化疗期间心肌微循环变化。

核心结论

  • 妇科恶性肿瘤患者中心肌微血管功能障碍与化疗治疗相关,静息心脏磁共振首过灌注可评估和监测该改变;化疗与心肌微血管功能障碍相关但未使其加重。

研究设计与样本

  • 前瞻性研究,纳入81例接受化疗的妇科恶性肿瘤患者和39名健康志愿者,其中32例患者完成中位间隔6个月的心脏磁共振随访;序列包括心脏电影、静息首过灌注和延迟钆增强。

关键影像表现/征象

  • 与正常对照相比,化疗患者心肌灌注指数降低:正常对照12%(11%至14%)vs 化疗患者13.62±2.01%,p=0.001。
  • 随访时化疗患者心肌灌注指数随化疗周期数增加无显著变化:11.79±2.36% vs 11.19±2.19%,p=0.234。

诊断标准与关键数值

  • 心肌灌注指数(PI)用于评估心肌微血管功能,患者组为13.62±2.01%,正常对照组为12%(11%至14%),组间差异p=0.001。
  • 多因素分析校正临床混杂因素后,灌注指数降低与化疗治疗独立相关(β=-0.362,p=0.002),与化疗周期数无相关性(r=-0.177,p=0.053)。

临床应用与阅片要点

  • 静息心脏磁共振首过灌注可用于评估和监测化疗期间心肌微循环改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Cancer chemotherapy potentially increases the risk of myocardial ischemia. This study assessed myocardial microvascular function by cardiac magnetic resonance (CMR) first-pass perfusion in patients treated with chemotherapy for gynecologic malignancies.

METHODS: A total of 81 patients treated with chemotherapy for gynecologic malignancies and 39 healthy volunteers were prospectively enrolled and underwent CMR imaging. Among the patients, 32 completed CMR follow-up, with a median interval of 6 months. The CMR sequences comprised cardiac cine, rest first-pass perfusion, and late gadolinium enhancement.

RESULTS: There were no significant differences in the baseline characteristics between the patients and normal controls (all p > 0.05). Compared with the normal controls, the patients had a lower myocardial perfusion index (PI) (13.62 ± 2.01% vs. 12% (11 to 14%), p = 0.001) but demonstrated no significant variation with an increase in the number of chemotherapy cycles at follow-up (11.79 ± 2.36% vs. 11.19 ± 2.19%, p = 0.234). In multivariate analysis with adjustments for clinical confounders, a decrease in the PI was independently associated with chemotherapy treatment (β = - 0.362, p = 0.002) but had no correlation with the number of chemotherapy cycles (r = - 0.177, p = 0.053).

CONCLUSION: Myocardial microvascular dysfunction was associated with chemotherapy treatment in patients with gynecologic malignancies, and can be assessed and monitored by rest CMR first-pass perfusion.

KEY POINTS: • Chemotherapy was associated with but did not aggravate myocardial microvascular dysfunction in patients with gynecologic malignancies. • Rest CMR first-pass perfusion is an ideal modality for assessing and monitoring alterations in myocardial microcirculation during chemotherapy treatment.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang, Li, Wang, et al. Myocardial microvascular function assessed by CMR first-pass perfusion in patients treated with chemotherapy for gynecologic malignancies. Eur Radiol. 2022. PMID: 35579712. doi:10.1007/s00330-022-08823-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。